Wan Yushan

Wan Yushan, listed as chief executive, appears in our data through filings on Simcere Pharmaceutical Group Ltd. shares, published by HKEX. Between 12 November 2021 and 9 November 2025, the trades on record add up to 14 filings.

Both buying and selling appear: 8 purchases worth €2.7M, against 4 sales. The amount is not disclosed for 5 filings. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Since January 2026: no purchases and 1 sale on the market.

A typical purchase (the median) is worth €66k. Of 7 purchases, 2 formed part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The newest entry dates from 27 April 2026: an open-market sale, in Simcere Pharmaceutical Group Ltd. The last purchase on record was published on 27 August 2024, which is 788 days ago. The median gap between a trade and its publication by HKEX is 4 days. The shorter that gap, the sooner other investors can see what insiders have done. This summary is built from HKEX disclosures alone and does not predict where the share price will go.